{"id":"https://openalex.org/W2109076938","doi":"https://doi.org/10.1200/jco.2008.21.6093","title":"Project Zero Delay: A Process for Accelerating the Activation of Cancer Clinical Trials","display_name":"Project Zero Delay: A Process for Accelerating the Activation of Cancer Clinical Trials","publication_year":2009,"publication_date":"2009-08-04","ids":{"openalex":"https://openalex.org/W2109076938","doi":"https://doi.org/10.1200/jco.2008.21.6093","mag":"2109076938","pmid":"https://pubmed.ncbi.nlm.nih.gov/19652061"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.21.6093","doi":"https://doi.org/10.1200/jco.2008.21.6093","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.21.6093","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030742145","display_name":"Susan R. Pilat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Pilat","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038229490","display_name":"Marcel Bartolazzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marcel Bartolazzi","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066645066","display_name":"Dwana Sanders","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dwana Sanders","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013487780","display_name":"Jill Van Wart Hood","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jill Van Wart Hood","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110016266","display_name":"Stanley D. Tucker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stanley D. Tucker","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055445076","display_name":"Kevin P. Webster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Webster","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047131388","display_name":"Michael A. Mallamaci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Mallamaci","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041292801","display_name":"Steven Strand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Strand","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034819975","display_name":"Eileen Babcock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eileen Babcock","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067595997","display_name":"Robert C. Bast","orcid":"https://orcid.org/0000-0003-4621-8462","observed_orcids":["https://orcid.org/0000-0003-4621-8462"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert C. Bast","raw_affiliation_strings":["From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":1.6728,"has_fulltext":false,"cited_by_count":22,"citation_normalized_percentile":{"value":0.84660918,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"27","issue":"26","first_page":"4433","last_page":"4440"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.5824999809265137,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.5824999809265137,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.149399995803833,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12168","display_name":"Health and Medical Research Impacts","score":0.14749999344348907,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-clinical-trials","display_name":"cancer clinical trials","score":0.8370000123977661},{"id":"https://openalex.org/keywords/bureaucratic-delays","display_name":"bureaucratic delays","score":0.6639999747276306},{"id":"https://openalex.org/keywords/fda-regulatory-process","display_name":"FDA regulatory process","score":0.6460000276565552},{"id":"https://openalex.org/keywords/university-industry-collaboration","display_name":"university-industry collaboration","score":0.7770000100135803},{"id":"https://openalex.org/keywords/strategic-alliances","display_name":"strategic alliances","score":0.5860000252723694},{"id":"https://openalex.org/keywords/patient-safety","display_name":"patient safety","score":0.5820000171661377},{"id":"https://openalex.org/keywords/md-anderson-cancer-center","display_name":"MD Anderson Cancer Center","score":0.8949999809265137},{"id":"https://openalex.org/keywords/astrazeneca","display_name":"AstraZeneca","score":1.0}],"concepts":[{"id":"https://openalex.org/C4438859","wikidata":"https://www.wikidata.org/wiki/Q186117","display_name":"Timeline","level":2,"score":0.8192744255065918},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6698302626609802},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6470046639442444},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.6299364566802979},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.6122523546218872},{"id":"https://openalex.org/C2780385302","wikidata":"https://www.wikidata.org/wiki/Q367158","display_name":"Protocol (science)","level":3,"score":0.4921197295188904},{"id":"https://openalex.org/C2777106319","wikidata":"https://www.wikidata.org/wiki/Q362104","display_name":"Institutional review board","level":2,"score":0.41174620389938354},{"id":"https://openalex.org/C21547014","wikidata":"https://www.wikidata.org/wiki/Q1423657","display_name":"Operations management","level":1,"score":0.3202754855155945},{"id":"https://openalex.org/C545542383","wikidata":"https://www.wikidata.org/wiki/Q2751242","display_name":"Medical emergency","level":1,"score":0.29725176095962524},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.23929381370544434},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.1893760859966278},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C95457728","wikidata":"https://www.wikidata.org/wiki/Q309","display_name":"History","level":0,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C166957645","wikidata":"https://www.wikidata.org/wiki/Q23498","display_name":"Archaeology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":"Q000331","qualifier_name":"legislation & jurisprudence","is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D035843","descriptor_name":"Biomedical Research","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2008.21.6093","doi":"https://doi.org/10.1200/jco.2008.21.6093","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.21.6093","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:19652061","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19652061","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W1895993106","https://openalex.org/W1969947031","https://openalex.org/W2028330119","https://openalex.org/W2043103956","https://openalex.org/W2108747565","https://openalex.org/W2121175754","https://openalex.org/W2146250050"],"related_works":["https://openalex.org/W2549773109","https://openalex.org/W2596844901","https://openalex.org/W2892475780","https://openalex.org/W4399280970","https://openalex.org/W2319164287","https://openalex.org/W2097284043","https://openalex.org/W2767305048","https://openalex.org/W3004001779","https://openalex.org/W4415535057","https://openalex.org/W2889385369"],"abstract_inverted_index":{"Drug":[0,39,127,219],"development":[1],"in":[2,159,181,200],"cancer":[3],"research":[4],"is":[5,14],"lengthy":[6],"and":[7,38,41,72,90,103,113,126,146,170,177,195,210,218],"expensive.":[8],"One":[9],"of":[10,17,44,79,105,130,136,175,205,245,255],"the":[11,15,35,42,58,77,134,191,196,206,224,243,253],"rate-limiting":[12],"steps":[13],"initiation":[16],"first-in-human":[18,189],"(phase":[19],"I)":[20],"trials.":[21,162],"Three":[22],"to":[23,50,62,156],"6":[24],"months":[25],"can":[26,241],"elapse":[27],"between":[28,140],"investigational":[29],"new":[30,246],"drug":[31],"(IND)":[32],"approval":[33,117,129],"by":[34,94,227],"US":[36,124,216],"Food":[37,125,217],"Administration":[40,128,220],"entry":[43],"a":[45,137,150,187],"first":[46,197],"patient.":[47],"Issues":[48],"related":[49],"patient":[51,198,250],"participation":[52],"have":[53,66],"been":[54,154],"well":[55],"analyzed,":[56],"but":[57],"administrative":[59,84,179,239],"processes":[60,85,121,180],"relevant":[61],"implementing":[63,160],"clinical":[64,99,106,161,234,256],"trials":[65],"received":[67],"less":[68],"attention.":[69],"While":[70],"industry":[71],"academia":[73],"often":[74],"partner":[75],"for":[76,109,118],"performance":[78],"phase":[80],"I":[81],"studies,":[82],"their":[83,91],"are":[86],"generally":[87],"performed":[88],"independently,":[89],"timelines":[92],"driven":[93],"different":[95],"priorities:":[96],"safety":[97,251],"reviews,":[98],"operations,":[100],"regulatory":[101],"submissions,":[102],"contracting":[104],"delivery":[107],"vendors":[108],"industry;":[110],"contracts,":[111],"budgets,":[112],"institutional":[114],"review":[115],"board":[116],"academia.":[119],"Both":[120],"converge":[122],"on":[123,166],"an":[131],"IND.":[132],"In":[133,186],"context":[135],"strategic":[138],"alliance":[139],"M.":[141],"D.":[142],"Anderson":[143],"Cancer":[144],"Center":[145],"AstraZeneca":[147],"Pharmaceuticals":[148],"LP,":[149],"concerted":[151],"effort":[152],"has":[153],"made":[155],"eliminate":[157],"delays":[158,240],"These":[163],"efforts":[164],"focused":[165],"close":[167],"communications,":[168],"identifying":[169],"matching":[171],"key":[172],"timelines,":[173],"alignment":[174],"priorities,":[176],"tackling":[178],"parallel,":[182],"rather":[183],"than":[184],"sequentially.":[185],"recent,":[188],"trial,":[190],"study":[192,208],"was":[193],"activated":[194],"identified":[199],"46":[201],"days":[202],"from":[203],"completion":[204],"final":[207,215],"protocol":[209],"about":[211,228],"48":[212],"hours":[213],"after":[214],"IND":[221],"approval,":[222],"reducing":[223],"overall":[225],"timeline":[226],"3":[229],"months,":[230],"while":[231],"meeting":[232],"all":[233],"good":[235],"practice":[236],"guidelines.":[237],"Eliminating":[238],"accelerate":[242],"evaluation":[244],"drugs":[247],"without":[248],"compromising":[249],"or":[252],"quality":[254],"research.":[257]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}